Latest News
Conference Coverage
Ofatumumab shows high elimination of disease activity in MS
The once-per-month self-injected therapy could offer an alternative to DMTs that require in-office infusion.
From the Journals
COVID-19: Putting distance between projection and reality
Curves have been flattened, but easing of social distancing without increasing other measures risks rapid resurgence.
Latest News
Today’s top news highlights: Coping with addiction during COVID, lung rehab part of recovery
Seriously ill COVID-19 patients face long-term health consequences.
Conference Coverage
Natalizumab switch to moderate-efficacy DMT increases disability risk
“Patients transitioning from natalizumab to another high-efficacy therapy have better inflammatory and disability outcomes, compared with those...
Conference Coverage
High levels of air pollution linked to increased MS risk
“Countermeasures that cut air pollution can be important for public health, not only to reduce deaths related to cardiac and pulmonary diseases...
From the Journals
Placental injury reported in women with COVID-19
A first-of-its-kind study looks at the extent and implications of pathological damage to the placentas of mothers with COVID-19.
From the Journals
SARS-CoV-2 infection rate 16% in asymptomatic pregnant women at delivery
Infection rates in the women’s support persons were 10%.
From the Journals
Whether to test laboring women for SARS-CoV-2 may hinge on regional prevalence
In Los Angeles, researchers stopped universal testing after none of the first asymptomatic women had positive results. In Chicago, they detected...
Feature
A long road to recovery: Lung rehab needed after COVID-19
These patients “get sick very fast, and it takes a long time for them to heal. What’s not really well appreciated is how much rehab and how much...
From the Journals
‘The story unfolding is worrisome’ for diabetes and COVID-19
Diabetes Care has published a host of new articles on diabetes and COVID-19 infection, as NIDDK researchers also acknowledge risks to other organ...
Conference Coverage
Mixed results for aducanumab in two phase 3 trials for Alzheimer’s disease
One of two “identical studies” assessing a novel treatment in development for Alzheimer’s disease reports significant efficacy, while the other...